Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in CP-CML Not in Complete Cytogenetic Remission
NCT00072579Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2003
- Primary completion
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in chronic myeloid leukemia (CML), sponsored by Wake Forest University Health Sciences. Primary endpoint: Cytogenetic response (complete and partial) at 12 months. Started May 2003; status: completed.
02
Drugs
sargramostim
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00072579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072579.